N-myristoyl transferase inhibitors

1. A method of treating an N-myristoyl transferase (NMT) related disease or disorder in a subject, wherein the disease or disorder is cancer selected from the group consisting of cancers of the lung, breast, esophagus, blood, glioma, bladder, fibrosarcoma and colon, or a parasitic infection resulting from T. brucei brucei , the method comprising administering to said subject a therapeutically effective amount of a compound of formula (IV)(ii) or a pharmaceutically acceptable salt or pro-drug thereof:

wherein

n is 0;

W and X, one of which may be absent, are independently selected from a hydrocarbyl group optionally substituted with R 11 , and

a —(CH 2 ) k -heterocyclyl-group optionally substituted with R 12 , wherein k is 0, 1, 2, 3, 4, 5 or 6;

R 1 , R 2 , R 4 and R 5 are independently selected from hydrogen, R 12 , a hydrocarbyl group optionally substituted with R 12 , and a —(CH 2 ) l -heterocyclyl optionally substituted with R 12 , wherein 1 is 0, 1, 2, 3, 4, 5 or 6, wherein R 1 and R 2 taken together with the atoms to which they are attached may form a heterocycle optionally substituted with one or more R 12 , wherein R 1 and/or R 2 taken together with W or X may form a heterocycle optionally substituted with one or more R 12 , and wherein one or more of R 3 and R 5 taken together with the atoms to which they are attached may form a carbocycle or a heterocyclyl group optionally substituted with R 12 ;

wherein each R 11 and R 12 is independently selected from halogen, trifluoromethyl, cyano, thio, nitro, oxo, ═NR 13 , —OR 13 , —SR 13 , —C(O)R 13 , —C(O)OR 13 , —OC(O)R 13 , —NR 13 COR 14 , —NR 13 CONR 13 2 , —NR 13 CO 2 R 14 , —S(O)R 13 , —S(O) 2 R 13 , —SONR 13 2 , —NR 13 S(O) 2 R 14 , —CSR 13 , —N(R 13 )R 14 , —C(O)N(R 13 )R 14 , —SO 2 N(R 13 )R 14 and R 15 ;

wherein R 13 and R 14 are each independently hydrogen or R 15 ;

wherein R 15 is selected from a hydrocarbyl group, a carbocyclyl group and a —(CH 2 ) m -heterocyclyl group wherein m is 0, 1, 2, 3, 4, 5 or 6, and each R 15 is optionally and independently substituted with one or more of halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy groups;

R 3a , R 3b , R 3c and R 3d are independently selected from hydrogen, halogen, R 12 , a C 1-6 alkyl group, a C 1-6 alkenyl group, a C 1-6 alkynyl group, a C 1-6 haloalkyl group, wherein the C 1-6 alkyl group, the C 1-6 alkenyl group, the C 1-6 alkynyl group, and the C 1-6 haloalkyl group optionally are substituted with R 12 , and a —(CH 2 ) l -heterocyclyl group optionally substituted with R 12 ; and

q is 0, 1, 2, 3 or 4, wherein the values of R 5 may be the same or different.

2. The method of claim 1 , wherein the compound is of formula (IV)(iii)

wherein R 3a and R 3b are independently selected from hydrogen, halogen R 12 , a C 1-6 alkyl group, a C 1-6 alkenyl group, a C 1-6 alkynyl group, a C 1-6 haloalkyl group, wherein the C 1-6 alkyl group, the C 1-6 alkenyl group, the C 1-6 alkynyl group, and the C 1-6 haloalkyl group optionally are substituted with R 12 , and a —(CH 2 ) l -heterocyclyl group optionally substituted with R 12 ,

R 5a , R 5b and R 5c are independently selected from hydrogen, R 12 , a C 1-6 alkyl group, a C 1-6 alkenyl group, a C 1-6 alkynyl group, a C 1-6 haloalkyl group, wherein the C 1-6 alkyl group, the C 1-6 alkenyl group, the C 1-6 alkynyl group, and the C 1-6 haloalkyl group optionally are substituted with R 12 , and a —(CH 2 ) l -heterocyclyl group optionally substituted with R 12 ,

wherein R 1 , R 2 , R 4 , R 12 , W, X, l and n are as defined in claim 1 .

3. The method of claim 1 , wherein each R 5 group independently is a hydrogen or an alkyl group.